The demand for Lipid-Lowering Agents in Central & Western Europe has been on the rise in recent years.
Customer preferences: The increase in demand can be attributed to the growing awareness of the importance of maintaining healthy cholesterol levels, particularly in the aging population. Additionally, the rise in the prevalence of obesity and related health issues has also contributed to the growth of the market.
Trends in the market: Germany and France are the largest markets for Lipid-Lowering Agents in the region, driven by the high incidence of cardiovascular diseases in these countries. The market is expected to continue growing due to the aging population and the increasing prevalence of obesity. Furthermore, the introduction of new drugs and therapies is expected to boost the market growth in the coming years.
Local special circumstances: In Germany, the government has implemented measures to control the rising healthcare costs, which has led to the introduction of generic drugs. This has resulted in the availability of cost-effective drugs, which has increased the demand for Lipid-Lowering Agents in the country. In France, the government has implemented a national health insurance system, which covers a significant portion of the population, leading to increased access to healthcare services.
Underlying macroeconomic factors: The Lipid-Lowering Agents market in Central & Western Europe is influenced by various macroeconomic factors such as the aging population, rising healthcare costs, and increasing prevalence of chronic diseases. Additionally, the growing demand for personalized medicine and the increasing adoption of digital healthcare technologies are expected to drive the market growth in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
